Mark P. Chao

14.6k citations

73 papers · 8.5k indexed · 6 hit papers · h-index 31

Impact in

Immunology top 0.2%
- Phagocytosis and Immune Regulation
- Immune cells in cancer
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
Hematology top 0.5%
- Acute Myeloid Leukemia Research

Papers in

Immunology 50
- Phagocytosis and Immune Regulation 48
- Immune cells in cancer 12
- Immunotherapy and Immune Responses 9
- Complement system in diseases 7
Hematology 20
- Acute Myeloid Leukemia Research 17

Co-authors: Irving L. Weissman Ravindra Majeti Siddhartha Jaiswal Ash A. Alizadeh Wendy W. Pang Nico van Rooijen Christopher Y. Park Kenneth D. Gibbs
Journals: Journal of Clinical Oncology (15 papers)Blood (15 papers)Cell (3 papers)Proceedings of the National Academy of Sciences (3 papers)Cancer Immunology Research (2 papers)
Partner nations: United States United Kingdom India

In The Last Decade

Mark P. Chao

71 papers receiving 8.4k citations

Hit Papers

6 papers align trajectories log scale

The CD47–SIRPα pathway in cancer immune evasion and potential therapeutic implications 2012 · 509 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2012 Current Opinion in Immunology
2010 Cell
2010 Science Translational Medicine
2009 Cell
2009 Cell
2009 Proceedings of the National Academy of Sciences

Peers

Countries citing papers authored by Mark P. Chao

Since Specialization

Citations

This map shows the geographic impact of Mark P. Chao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark P. Chao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark P. Chao more than expected).

Fields of papers citing papers by Mark P. Chao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark P. Chao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark P. Chao. The network helps show where Mark P. Chao may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Mark P. Chao, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark P. Chao Line = papers co-authored together Mark P. Chao links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Intra-Leukemic Interferon Signaling Suppresses Expansion and Mediates Chemoresistance in Human AML Blood Cancer Discovery ·Daiki Karigane, Amy C. Fan, Toshinobu Nishimura, Kensuke Kayamori, Yusuke Nakauchi, Thomas Köhnke, احمد فرحان مصلح, Asiri Ediriwickrema, Zongjun Hu, Rozario Thomas, 恒吉忠雄, Melissa Stafford, Fabian P. Suchy, Jonas L. Fowler, Mark P. Chao, Tian Yi Zhang, Kyle M. Loh, Hiromitsu Nakauchi, Ravindra Majeti	2025	0
2	slan+ Monocytes Kill Cancer Cells Coated in Therapeutic Antibody by Trogoptosis Cancer Immunology Research ·Waldo Garrido, Enrica Pietronigro, Ye Won Jun, Silvia Lonardi, Gabriela Constantin, Mark P. Chao, Cristina Tecchio, William Vermi, Marco A. Cassatella	2023	7
3	Combined Blockade of CD47-Sirpa Interaction By 5F9 (Magrolimab) and Azacitidine/Venetoclax Therapy Facilitates Macrophage-Mediated Anti-Leukemia Efficacy in AML Pre-Clinical Models Blood ·Yannan Jia, Qi Zhang, Connie C. Weng, انسیه فرهیدزاده, Yuki Nishida, Mark P. Chao, Roy L. Maute, Shelley M. Herbrich, Weiguo Zhang, Michael Andreeff, Naval Daver, Marina Konopleva	2021	15
4	A Phase 2, Open-Label, Multiarm, Multicenter Study to Evaluate Magrolimab Combined with Antileukemia Therapies for First-Line, Relapsed/Refractory, or Maintenance Treatment of Acute Myeloid Leukemia Blood ·Paresh Vyas, Naval Daver, Mark P. Chao, Guan Xing, Matheus Ch.A Latumahina, محمد بن سعيد الحويطي, Andrew H. Wei, David A. Sallman	2021	2
5	Macrophage Activation By Dual PI3K-δ/γ Inhibition Enhances Anti-CD47-Mediated Phagocytosis and Prolongs Survival in DLBCL Blood ·James Godfrey, Wenjun Kang, Lei Huang, Sílvia Coma, Roy L. Maute, Mark P. Chao, Jonathan A. Pachter, Sonali M. Smith, Justin Kline	2020	4
6	Energy-Dense versus Routine Enteral Nutrition in the Critically Ill New England Journal of Medicine ·Jens Volkmer, Mark P. Chao, Arthur A. Kola	2019	100
7	The Macrophage ‘Do not eat me’ signal, CD47, is a clinically validated cancer immunotherapy target Annals of Oncology ·Chris H. Takimoto, Mark P. Chao, C. Parker Gibbs, Mark McCamish, 박준현, Erdem Vergili, Ravindra Majeti, Irving L. Weissman	2019	90
8	Induced pluripotent stem cell modeling of malignant hematopoiesis Experimental Hematology ·Mark P. Chao, Ravindra Majeti	2019	5
9	Combination Treatment with 5F9 and Azacitidine Enhances Phagocytic Elimination of Acute Myeloid Leukemia Blood ·Dongdong Feng, Phung Gip, Kelly M. McKenna, Feifei Zhao, 一雄柳, Alexandra Löwy, 何祥林, 卫国赵, Ravindra Majeti, Irving L. Weissman, Chris H. Takimoto, Mark P. Chao, James Y. Chen, Jie Liu, Jens-Peter Volkmer	2018	52
10	RBC-Specific CD47 Pruning Confers Protection and Underlies the Transient Anemia in Patients Treated with Anti-CD47 Antibody 5F9 Blood ·James Y. Chen, Kelly M. McKenna, Alexandra Löwy, 何祥林, Lynette Brown, Jennifer J. Stewart, 卫国赵, Paresh Vyas, Stanley L. Schrier, Ravindra Majeti, Irving L. Weissman, Kyle Elrod, Mark P. Chao, Chris H. Takimoto, Jie Liu, Jens-Peter Volkmer	2018	14
11	Human AML-iPSCs Reacquire Leukemic Properties after Differentiation and Model Clonal Variation of Disease Cell stem cell ·Mark P. Chao, Andrew J. Gentles, Liuqing Ji, Feng Lan, Andreas Reinisch, M. Ryan Corces, Quansheng Ge, Jinfeng Shen, Daniel Haag, Soham Chanda, Rahul Sinha, Eliane de Sousa Caixeta, Toshinobu Nishimura, Mohamed Ameen, Haodi Wu, Marius Wernig, Joseph C. Wu, Ravindra Majeti	2017	90
12	Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential PLoS ONE ·Jie Liu, Lijuan Wang, Feifei Zhao, Serena Tseng, Cyndhavi Narayanan, Seng hun Min, Stephen B. Willingham, Maureen Howard, Susan Prohaska, Jens Volkmer, Mark P. Chao, Irving L. Weissman, Ravindra Majeti	2015	381
13	Treatment challenges in the management of relapsed or refractory non-Hodgkin’s lymphoma – novel and emerging therapies Cancer Management and Research ·Mark P. Chao	2013	78
14	Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia Cancer Research ·Mark P. Chao, Ash A. Alizadeh, Chad Tang, Max Jan, Rachel Weissman-Tsukamoto, Feifei Zhao, Christopher Y. Park, Irving L. Weissman, Ravindra Majeti	2010	294
15	Macrophages as mediators of tumor immunosurveillance Trends in Immunology ·Siddhartha Jaiswal, Mark P. Chao, Ravindra Majeti, Irving L. Weissman	2010	200
16	Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma Cell ·Mark P. Chao, Ash A. Alizadeh, Chad Tang, June H. Myklebust, Bindu Varghese, Saar Gill, Max Jan, Didem Kutlu, Charles K. F. Chan, Brent Tan, Christopher Y. Park, Feifei Zhao, Holbrook E. Kohrt, Raquel Malumbres, Javier Briones, Randy D. Gascoyne, Izidore S. Lossos, Ronald Levy, Irving L. Weissman, Ravindra Majeti Hit paper breakdown →	2010	845
17	CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis Cell ·Siddhartha Jaiswal, Catriona Jamieson, Wendy W. Pang, Christopher Y. Park, Mark P. Chao, Ravindra Majeti, David Traver, Nico van Rooijen, Irving L. Weissman Hit paper breakdown →	2009	1210
18	CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells Cell ·Ravindra Majeti, Mark P. Chao, Ash A. Alizadeh, Wendy W. Pang, Siddhartha Jaiswal, Kenneth D. Gibbs, Nico van Rooijen, Irving L. Weissman Hit paper breakdown →	2009	1340
19	Establishment of a Normal Hematopoietic and Leukemia Stem Cell Hierarchy Cold Spring Harbor Symposia on Quantitative Biology ·Mark P. Chao, Jun Seita, Irving L. Weissman	2008	101
20	Autoimmune VH gene family: PCR-generated murine germline VH10 genes Molecular Immunology ·Mark P. Chao, Edward W. Voss	1992	3

About Mark P. Chao

Mark P. Chao is a scholar working on Immunology, Hematology, Genetics, Oncology and Physiology, having authored 73 papers that have together received 8.5k indexed citations. Recurring topics across this work include Phagocytosis and Immune Regulation (48 papers), Acute Myeloid Leukemia Research (17 papers), Erythrocyte Function and Pathophysiology (13 papers), CAR-T cell therapy research (12 papers), Immune cells in cancer (12 papers), Chronic Lymphocytic Leukemia Research (10 papers), Immunotherapy and Immune Responses (9 papers) and Complement system in diseases (7 papers). The work is most often cited by research in Immunology (5.3k citations), Hematology (1.6k citations), Oncology (2.6k citations), Genetics (629 citations) and Physiology (1.3k citations). Mark P. Chao has collaborated with scholars based in United States, United Kingdom and India. Frequent co-authors include Irving L. Weissman, Ravindra Majeti, Siddhartha Jaiswal, Ash A. Alizadeh, Wendy W. Pang, Nico van Rooijen, Christopher Y. Park, Kenneth D. Gibbs, Catriona Jamieson and David Traver. Their work appears in journals such as Journal of Clinical Oncology, Blood, Cell, Proceedings of the National Academy of Sciences and Cancer Immunology Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact